1、August 7,2025For release:ImmediatelyRefer to:Ashley Hennessey;gentry_ashley_;(317)416-4363(Media)Mike Czapar;czapar_michael_;(317)617-0983(Investors)Lilly reports second-quarter 2025 financial results and raises guidanceRevenue in Q2 2025 increased 38%to$15.56 billion driven by volume growth from Ze

2、pbound and Mounjaro.Increased the midpoint of our 2025 full-year revenue guidance by$1.5B to be in the range of$60 billion to$62 billion;reported EPS guidance raised to be in the range of$20.85 to$22.10 and non-GAAP EPS guidance raised to be in the range$21.75 to$23.00Pipeline progress included posi

3、tive results in orforglipron for obesity,Mounjaro SURPASS CVOT for type 2 diabetes and heart disease,and Jaypirca H2H vs Imbruvica in CLL/SLL.Q2 2025 EPS increased 92%to$6.29 on a reported basis and increased 61%to$6.31 on a non-GAAP basis,both inclusive of$0.14 of acquired IPR&D charges.Busines

4、s development activity included the completed acquisitions of SiteOne Therapeutics,Inc.and Verve Therapeutics,Inc.INDIANAPOLIS,August 7,2025-Eli Lilly and Company(NYSE:LLY)today announced its financial results for the second-quarter of 2025.“Lilly delivered another quarter of strong performance,achi

5、eving 38%year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines,”said David A.Ricks,Lilly chair and CEO.“Our pipeline continued to advance,highlighted by positive study results in oncology and cardiometabolic healthincluding Moun

6、jaros demonstrated cardio-protective effects in patients with type 2 diabetes and heart disease and strong data for our oral incretin,orforglipron,in obesity.We also expanded manufacturing capacity to meet increasing demand and invested in key R&D initiatives to support our long-term growth.”Eli